Stomach Neoplasms
Conditions
Keywords
Stomach Neoplasms, Secondary, Combination chemotherapy, S-1, irinotecan, oxaliplatin
Brief summary
Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1 and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessement will be performed every 2 cycles of chemotherapy.
Interventions
DRUGIrinotecan, Oxaliplatin, TS-1
* S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning) * Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1 * Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1
Sponsors
National Cancer Center, Korea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed gastric adenocarcinoma with recurrent or metastatic disease 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 4. Disease status must be that of measurable disease as defined by RECIST criteria:Measurable lesions: Lesions that can be accurately measured in at least one dimension by any of the following: - CT of abdomen, pelvis or thorax, if the longest diameter to be recorded is at least 10 mm with spiral CT- Chest x-ray, if the lung lesion to be recorded is clearly defined and surrounded by aerated lung and the diameter to be recorded is at least 20 mm- Physical examination, if the clinically detected lesions are superficial (e.g., skin nodule and palpable lymph nodes) and at least 10 mm 5. No prior treatment for recurrent or metastatic disease; prior adjuvant/neoadjuvant therapy is allowed if at least 12 months have elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study. However, prior oxaliplatin and/or irinotecan as adjuvant therapy are not allowed. 6. Adequate major organ function including the following: Hematopoietic function: ANC ³ 1,500/mm3, Platelet ³ 100,000/mm3Hepatic function: serum bilirubin 1.5 mg/dl, AST/ALT levels 2.5 x UNL ( 5 x UNL if liver metastases are present)Renal function: serum creatinine UNL 7. Patients should sign a written informed consent before study entry
Exclusion criteria
1. Prior history of peripheral neuropathy 2. Inadequate cardiovascular function:New York Heart Association class III or IV heart diseaseUnstable angina or myocardial infarction within the past 6 monthsHistory of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality 3. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy 4. Other malignancy within the past 3 years except non-melanomatous skin cancer or carcinoma in situ of the cervix 5. Psychiatric disorder that would preclude compliance 6. Pregnant, nursing women or patients with reproductive potential without contraception 7. Patients receiving a concomitant treatment with drugs interacting with S-1 such as flucytosine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximal overall response rate | During chemotherapy |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes | during study period |
Countries
South Korea
Outcome results
None listed